FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services

The Food and Drug Administration (FDA) approved injectable doxorubicin HCl liposome (DOXIL) for treatment of Kaposi's sarcoma (KS) in AIDS patients. DOXIL's major benefit is that its reported circulating half-life is fifty hours, compared to ten minutes for free (non-liposome) doxorubicin.